Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
14 mars 2023 16h05 HE
|
Arbutus Biopharma Corporation
Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coronaviruses WARMINSTER, Pa., March 14,...
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
02 mars 2023 07h30 HE
|
Arbutus Biopharma Corporation
Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for...
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
16 févr. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus to Participate in Three Upcoming Investor Conferences
06 févr. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Announces Resignation of Board Member
27 janv. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
05 janv. 2023 07h30 HE
|
Arbutus Biopharma Corporation
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into...
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
13 déc. 2022 07h30 HE
|
Arbutus Biopharma Corporation
Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from IFN phase expected in the first half of 2023 WARMINSTER, Pa., Dec. 13, 2022 (GLOBE...
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
09 nov. 2022 07h30 HE
|
Arbutus Biopharma Corporation
Financially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after...
Arbutus to Present at Jefferies London Healthcare Conference
08 nov. 2022 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
01 nov. 2022 16h01 HE
|
Arbutus Biopharma Corporation
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in...